SLCO1B1 and hematologic disorder: A recent study in adult patients with hematologic malignancies receiving high-dose methotrexate suggests that patients with the SLCO1B1 A388G or T521C variants exhibit differential metabolomic profiles that may modulate the risk for methotrexate-induced toxicities.